IAP antagonist (Chung-Ang University/Hanmi Pharmaceutic)

N/A

Report date: 2025/01/26 18:28:36
NME

Base Information

Drug NameIAP antagonist (Chung-Ang University/Hanmi Pharmaceutic)
Drug Alias Namequinazoline-based SMAC (Chung-Ang University/Hanmi Pharmaceutical)quinazoline-based second mitochondria-derived activator of caspases (Chung-Ang University/Hanmi Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of apoptosis protein 3 inhibitors
TargetsInhibitor of apoptosis protein 3
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChung-Ang University
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdChung-Ang University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A